Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease Clinical Trial

Official title:

A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Autologous MitoCell (Adipose-Derived Mesenchymal Stem Cells) Transplantation in Subjects With Idiopathic Parkinson's Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05094011
• Other study ID #: MITOCELL-01
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: March 1, 2025
• Est. completion date: July 31, 2027

Study information

• Verified date: April 2023
• Source: Taiwan Mitochondrion Applied Technology Co., Ltd.
• Contact: Kuo-Wei Hsueh, Ph. D.
• Phone: 886-03-5820208
• Email: fskenneth[@]taimito.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective: To assess the safety profile of autologous MitoCell administered to subjects with idiopathic Parkinson's disease (PD) Secondary Objective: To explore the efficacy and safety of MitoCell given as the recommended dose by stereotactic intrastriatal implantation

Description:

MitoCell is an autologous stem cell product that cultures with the company's unique patented medium. The mechanism of action of MitoCell is to improve the brain microenvironment in neurodegenerative disease. MitoCell which like mesenchymal stem cells modulate the immune response, and secrete more BDNF and SDF-1 neurotrophic factors than regular stem cell products.Therefore, MitoCell can protect and repair damaged dopamine neurons (DA) and stimulate DA regeneration.This project is a phase I open-label dose-escalation study to evaluate the safety, tolerability, and efficacy of autologous MitoCell intracranial transplantation in subjects with idiopathic Parkinson's disease which rating from stage 3 ~ 4 of modified Hoehn & Yahr staging.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 9
• Est. completion date: July 31, 2027
• Est. primary completion date: September 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 70 Years

Eligibility

Inclusion Criteria:

• Provision of signed and dated informed consent form
• Aged 45 to 70 years old (inclusive) at Screening
• Idiopathic Parkinson's disease patients who meet the diagnostic criteria of the "Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease"
• With at least 5 years since the diagnosis of Parkinson's disease
• With responsiveness to levodopa or dopa agonist. This is defined as improvement between ''Off'' and ''On'' MDS-UPDRS by at least 33% of the Motor MDS-UPDRS
• Idiopathic Parkinson's disease of Stage 3 ~ 4 of modified Hoehn & Yahr staging during ''ON'' time
• Stable Parkinsonian medications for at least 2 months prior to the Screening Visit
• MRI not showing gross atrophy or any brain pathology other than PD
• Mini-Mental State Examination (MMSE) ? 24
• With score of the Beck Depression Inventory (BDI-II) < 29 and Hamilton Rating Scale for Depression (HAM-D-17) < 25

Exclusion Criteria:

• Atypical or secondary Parkinsonism
• With neurodegenerative disorders other than PD
• Unable to receive MRI or PET scanning
• With any concomitant disorder that would contraindicate coagulation, general anesthesia, or stereotactic neurosurgery
• Received any other investigational agent within 4 weeks prior to Screening
• History of intracranial surgeries or implantation of a device for Parkinson's disease 2 years prior to Screening
• Major surgery within the previous 6 months at Screening
• Significant cardiovascular disease, including:
• New York Heart Association (NYHA) class III or IV congestive heart failure
• Uncontrolled hypertension: Blood pressure >140/90 mmHg
• History of serious ventricular arrhythmia
• Malignancy within 2 years prior to Screening
• Any diagnosis of autoimmune disease or immune compromised state and requiring systemic steroid or immunosuppressive treatment
• Any other severe systemic disorder, including history of schizophrenia or other psychotic disorders, stroke, seizure, traumatic brain injury, or central nervous system infection, which judged by the investigator that entering the trial may be detrimental to the subject
• Psychiatric, addictive or any other disorder that compromises ability to give a truly informed consent and perform all study assessments
• Positive in any of the following regulatory authority-licensed screening tests:
• HIV antigen/antibody combo test
• Anti-HCV test
• Hepatitis B surface antigen (HBsAg) test
• Rapid plasma reagin (RPR) test
• HIV-1 nucleic acid test (NAT)
• HBV NAT
• HCV NAT
• Any of the following hematologic abnormalities:
• Hemoglobin < 9.0 g/dL,
• ANC < 1,500/µL
• Platelets < 100,000/µL
• Any of the following serum biochemistry abnormalities:
• Total bilirubin > 1.5 × ULN
• AST or ALT > 2.5 × ULN
• r-GT > 2.5 × ULN
• ALP > 2.5 × ULN
• serum albumin < 3.0 g/dL
• creatinine > 1.5 × ULN
• Female subject who is lactating or has positive serum or urine pregnancy test at Screening Visit
• Female subject with childbearing potential or male subject with female spouse/partner with childbearing potential who refuses to adopt at least two forms of birth control (at least one of which must be a barrier method) from Screening until Final/Early

Termination Visit. Acceptable forms include:

• Established use of oral, injected or implanted hormonal methods of contraception
• Placement of an intrauterine device (IUD) or intrauterine system (IUS)
• Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps)
• With any condition judged by the investigator that entering the trial may be detrimental to the subject

Related Conditions & MeSH terms

• Idiopathic Parkinson's Disease
• Parkinson Disease

Intervention

Biological:
• Aadipose-Derived Mesenchymal Stem Cells
Stereotactic intrastriatal implantation of 3×10^7 per hemisphere (total 6×10^7 cells) or 1×10^8 per hemisphere (total 2×10^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Taiwan Mitochondrion Applied Technology Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Grading of Adverse Events	Grading will be assessed using NCI CTCAE, version 5.0.	within 48 weeks after MitoCell transplantation
Primary	Routine physical examinations	Safety of Mitocell will be assessed by routine physical examinations. Physical examination conducted in this study will include general appearance, skin, eyes, ears, nose,throat, head and neck, heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal,neurological, etc.	within 48 weeks after MitoCell transplantation
Primary	Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell]	Clinical standard neurological examination by study investigator. Changes in motor function, sensory function, cranial nerve function (visual fields), cortical functions and reflexes are followed in the examination, scored as normal - abnormal without clinical relevance - abnormal with clinical relevance	within 48 weeks after MitoCell transplantation
Primary	Changes in vital signs: blood pressure [Safety of Mitocell]	Changes in blood pressure during the study , measured as systolic and diastolic blood pressure (in mmHg)	within 48 weeks after MitoCell transplantation
Primary	Changes in vital signs: pulse rate [Safety of Mitocell]	Changes in pulse rate during the study (in beats per minute)	within 48 weeks after MitoCell transplantation
Primary	Changes in vital signs: body temperature [Safety of Mitocell]	Changes in body temperature during the study (in degrees celsius)	within 48 weeks after MitoCell transplantation
Primary	Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell]	Changes in laboratory variables for haematology: hemoglobin (g/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance"	within 48 weeks after MitoCell transplantation
Primary	Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell]	Changes in laboratory variables for haematology: Platelet count (10E9/L). Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance"	within 48 weeks after MitoCell transplantation
Primary	Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell]	Changes in laboratory variables for haematology: Cell counts (10E9/L) for total WBC, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance"	within 48 weeks after MitoCell transplantation
Primary	Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell]	Changes in laboratory variables for haematology: INR (standardized prothrombin time) to determine the effects of oral anticoagulants on the clotting system. Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance"	within 48 weeks after MitoCell transplantation
Primary	Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell]	Changes in laboratory variables for haematology: aPTT (sec) . Result evaluated as "normal", "abnormal without clinical relevance" or "abnormal with clinical relevance"	within 48 weeks after MitoCell transplantation
Primary	Electrocardiogram (ECG)	Safety of Mitocell will be assessed by any clinically significant abnormalities on ECG results as compared to Baseline. A standard 12-lead ECG was measured by using ECG machine that automatically measured PR, QRS, QT, and QTcF intervals.	within 48 weeks after MitoCell transplantation
Primary	Magnetic Resonance Imaging (MRI)	Safety of Mitocell will be assessed by any clinically significant abnormalities on MRI scans as compared to Baseline.	within 48 weeks after MitoCell transplantation
Secondary	MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale)	Change in MDS-UPDRS motor (Part III) "OFF" score compared to the baseline. All items have 5 response options with uniform anchors of: 0 = normal, 1 = slight (symptoms/signs with sufficiently low frequency or intensity to cause no impact on function), 2 = mild (symptoms/signs of frequency or intensity sufficient to cause a modest impact on function, 3 = moderate (symptoms/signs sufficiently frequent or intense to impact considerably, but not prevent function), 4 = severe (symptoms/signs that prevent function).	at 12, 24, 48 weeks
Secondary	Modified Hoehn & Yahr staging	Change in Modified Hoehn & Yahr staging compared to the baseline.	at 12, 24, 48 weeks
Secondary	18F-DOPA PET	Degree of radiotracer uptake increment/decrement shown on striatum of 18F-DOPA PET compared to the baseline.	at 48 weeks
Secondary	levodopa equivalent daily dose (LEDD)	Reduction of Parkinson's medications consumption by calculating levodopa equivalent daily dose (LEDD) compared to the baseline.	at 12, 24, 48 weeks
Secondary	PDQ-39 (Parkinson's Disease Questionnaire)	Change in PDQ-39 scale compared to the baseline. The PDQ-39 is a 39 questions Parkinson's Disease self-completed questionnaire that comprises 8 domains: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items). All items are assumed to impact QoL and must be answered to compute scores for each dimension. Questions are answered based on experiences from the preceding month using a 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each scores range from 0 = never have difficulty to 100 = always have difficulty.	at 12, 24, 48 weeks
Secondary	Beck Depression Inventory (BDI-II) scores	Net change from baseline in BDI-II scores. BDI-II Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represents a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe). Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression.	at 48 weeks
Secondary	Hamilton Depression Rating Scale (HAM-D-17) scores	Net change from baseline in HAM-D-17 scores. The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed).	at 48 weeks
Secondary	Mini Mental State Examination (MMSE) Scores	Net change from baseline in MMSE scores. The MMSE uses a 30 point questionnaire to measure cognitive impairment. The MMSE is scored from 0 to 30,with a score equal to or greater than 24 points indicating normal cognition, a score of 19-23 points indicating mild cognitive impairment, 10-18 points indicating moderate impairment and a score equal to or below 9 indicating severe impairment.	at 48 weeks